Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Recruitment Status: Not yet recruiting"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22
/vufind/Search/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22
Search /vufind/Search2/Results?lookfor=%22Remission+Induction%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Not+yet+recruiting%22
PubPharm (42)
1
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
2
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
3
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
4
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
5
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD : Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD : Estudio de fase 3, doble ciego, multicéntrico, aleatorizado, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento profiláctico con anfotericina B liposomal (AmBisome®) para la prevención de infecciones fúngicas invasivas (IFI) en sujetos que reciben quimioterapia de inducción a la remisión para la leucemia linfoblástica aguda (LLA) - AmbiGUARD
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
3
4
5
Nächster »
[5]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Recruitment Status: Not yet recruiting
Medienart
42
Aufsätze
42
E-Artikel
42
E-Ressourcen
Zeitschriftentitel
42
WHO International Clinical Trials Registry Plat...
Thema
42
610
Recruitment Status: Not yet recruiting
42
Study Type: Interventional
30
Phase: Phase 3
10
Medical Condition: previously untreated acute m...
4
Medical Condition: Invasive fungal infections (...
4
Medical Condition: Invasive fungal infections (...
4
Medical Condition: previously untreated acute m...
4
Medical Condition: previously untreated acute m...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Invasive fungal infections (...
2
Medical Condition: Patients older than 60 years...
2
Medical Condition: previously untreated acute m...
2
Medical Condition: previously untreated acute m...
2
Medical Condition: previously untreated acute m...
2
Medical Condition: previously untreated acute m...
2
Phase: Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
22
2020-
20
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
40
Englisch
2
Spanisch
Haven't found what you're looking for?
Wird geladen...